The inspection was conducted from 12 February 2024 to 23 February 2024 and no Form 483 has been issued as a result of the inspection, stated the drug maker.

Suven Pharmaceuticals is in the business of Contract Development & Manufacturing Organisation (CDMO), catering to the needs of global pharma industry.

The pharmaceutical company reported 56.60% decline in consolidated net profit to Rs 46.75 crore on 37.86% fall in revenue from operations to Rs 219.82 crore in Q3 FY24 over Q3 FY23.

The scrip rose 0.85% to currently trade at Rs 669.20 on the BSE.